'''Siplizumab''' (MEDI-507) is a novel [[monoclonal antibody]] with a human [[IgG1]], kappa directed to [[CD2]]. The agent has shown potent [[immunomodulatory]] effects, selectively suppressing the function of [[T cell|T]] and [[NK cell]]s, and is currently being tested as a possible treatment for [[psoriasis]] and in the prevention of [[graft-versus-host disease]].<ref>[http://www.clinicaltrials.gov/ct2/results?term=Siplizumab ClinicalTrials.gov]</ref>
